In this year’s document, we explain:
- How we supported new Canadian immunotherapy translational research projects and clinical trials that have a realistic chance of reshaping the health system and changing patient outcomes.
- How we’ve helped move Canadian innovations closer to the market, and helped Canadian researchers mobilize successful findings.
- How we’ve trained more than 920 highly qualified personnel since 2015, expanding the Canadian workforce capable of discovering, making, and delivering new therapies.
- How we’re working with regulators and policymakers to strengthen the Canadian life sciences and research ecosystem.
- How we are partnering with patient groups and supporting equity-deserving communities to make sure that immunotherapies are developed and delivered for people who live across Canada.
We will also share information about how we’ve connected with communities across Canada, and provide our audited financial statements for the reporting period.
Note: no generative AI has been used in the writing of the annual report. However, to maximize accessibility for readers, we’ve designed this document to make it easier for AI to review, summarize, and find specific answers.